Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
Status: Recruiting
Location: See location...
Intervention Type: Genetic
Study Type: Observational
SUMMARY
Exploring the precise medicine of patients with primary hepatobiliary cancer. And evaluate the efficacy and safety of individualized treatment regimens for primary hepatobiliary cancer based on next-generation sequencing.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age from 18 to 65, male or female.
• Radiologically and pathologically confirmed as hepatobiliary cancers with stage IV.
• Palliative care as the preferred.
• The result of next-generation sequencing (NGS) test show the patient has gene mutation and also can be treated by the right commercial products that have been approved by the China Food and Drug Administration (CFDA) or the Food and Drug Administration (FDA).
• ECOG performance status 0-2.
• Life expectancy ≥3 months.
• Agree to sign informed consent form.
Locations
Other Locations
China
Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Bixiang Zhang, PhD
bixiangzhang@hust.edu.cn
86-027-83665293
Time Frame
Start Date: 2020-05-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 200
Treatments
Precise medicine
All patients should accept next-generation sequencing (NGS) test before treatment.
Related Therapeutic Areas
Sponsors
Leads: Tongji Hospital